ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.
- CAS No.
- Chemical Name:
- ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.
- Synonyms
- ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.
- CBNumber:
- CB35774730
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer. Preparation Products And Raw materials
Raw materials
Preparation Products
ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer. Suppliers
Global( 3)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hangzhou Yuxin Biotechnology Co., Ltd. | -- | haoxinbio@163.com | CHINA | 6595 | 58 |
| Xiamen Research Biotechnology Co., Ltd. | -- | 1562893815@qq.com | CHINA | 6936 | 58 |
| Xiamen Huijia Biological Technology Co., Ltd. | -- | CHINA | 6973 | 58 |
ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.